About Prevent-Plus

Reducing and treating infection is a significant global challenge. Bacteria, fungi and super-bugs that are resistant to current treatments are impacting individuals’ health on a daily basis, and in many cases are life threatening. The cost to treat these infections continues to mount with no end in sight.

Prevent-Plus, LLC was founded to acquire the intellectual property rights of Medpak, LLC (“Medpak”). On April 12, 2016 the asset acquisition was completed. Among the assets acquired were the approval from the United States Food and Drug Administration (“FDA”) to use Elastic Skin Liquid Bandage for certain specified applications (FDA (510)k No. K032948), United States Patent numbers 6909027 and 7119246 of the Elastic Skin Liquid Bandage, which has been rebranded as DuraDerm®.

The goal of Prevent-Plus is to help prevent infections globally by utilizing and expanding upon the intellectual property that Prevent-Plus, LLC, acquired from Medpak.

Prevent-Plus, LLC. is a company comprised of key strategic partners, including an esteemed physician, chemical engineer, Pharm. D., lawyer, hospital management, and pharmaceutical experts.

Brad Chartrand, Chief Executive Officer

Brad Chartrand is the Chief Executive Officer for Prevent Plus and is responsible for Global growth of the DuraDerm and DuraDerm Sport brands. Mr. Chartrand has over 15 years of Medical Device experience in various Sales and Marketing leadership roles with Applied Medical, CR BARD and AngioDynamics. Prior to Mr. Chartrand’s Medical Device career, he played 8 years of professional hockey, spending five seasons with the Los Angeles Kings (NHL).  Mr. Chartrand’s unique background is ideally suited to Prevent Plus’ hospital and OTC sports medicine segments. Mr. Chartrand did his undergraduate work at Cornell University and has MBA degrees from Cornell University and Queen’s University.

Jeffrey S. Elbl, Pharm.D., Chief Technology Officer

Jeff Elbl is the Chief Technology Officer for Prevent-Plus, LLC, and also currently the Director of Clinical Services for FocusScript, LLC (FS) where he oversees all clinical aspects of compounding medication utilization. Jeff also functions as a credentialing agent and visits pharmacies all over the country who wish to enter into the FS network of pharmacies. His other responsibility is marketing the FS network to pharmacy benefit managers and other payer groups with patients utilizing compounded medications. Jeff has over 12 years of direct patient care experience in the areas of infectious disease, antibiotic utilization, nutritional support, pharmacokinetic drug monitoring, pain management, anticoagulation therapy, oncology, wound management and many more. Jeff has extensive industry experience serving in the Medical Science Liaison (MSL) role for several major pharmaceutical companies including Pfizer, Bayer, and Millennium-The Takeda Oncology Company.

Immediately prior to joining FS, he was Senior Director of Clinical Services for one of the largest compounding pharmacy organizations in the United States. He has lectured all over the country on topics such as Improving Physician-Pharmacist  Communication, Pharmacoeconomics, Treatment of Multiple Myeloma, Pain Management and its complications, Cardiovascular Disease, Antibiotic Utilization, Community and Hospital Acquired Pneumonia, Treatment of Hypertension, Blood Sparing During Surgery, Management of Erectile Dysfunction, Wound Care, Nutritionals in Psychopharmacology, Individualized Medicine, and numerous other topics related to the practice of pharmacy and medication use. Jeff has been involved with several clinical trials as part of his role as an MSL.

Jeff’s special interest areas are Pain Management, Stage Specific Wound Care, Colorectal Health, Metabolic Supplementation, and Appropriate and Optimal Utilization of Medications. Jeff has been instrumental in the development, evaluation, and marketing of several novel products.

Joseph E. Thomure, Chairman/Managing Member

Because of his earnest belief in DuraDerm, Joe Thomure emerged from retirement to step into senior management in August 2018, purchasing the majority voting investment units of Prevent-Plus, LLC.

A graduate of the U.S Merchant Marine Academy in Kings Point, New York, Mr. Thomure served as a ship’s officer with Exxon and came ashore to engineering positions with Shell Oil in the inland barge industry. He was then called to active duty in the U.S. Navy, during which time he was promoted twice in three years, and eventually received his honorable discharge, pending LCDR in 1977. He began his business career in sales with Hallmark, and further refined his sales and consulting skills in executive and physician recruiting.

He founded his own recruiting firm, PracticeMatch, in 1987, bought out his competitors and IT contractors, partnered exclusively with the AMA, and then bundled the data into a physician recruiting database – a service concept that had never before existed. He sold this company for the first time in 1996, grouping with 11 other firms to form Caredata.com (stock symbol: CDCM).

After considering a brief retirement, he purchased a majority position from a NY venture group in IBNL,an early e-commerce company. As Chairman and CEO, he rebuilt the company as Virtual Source, and pushed value near $650 million while earning a NASDAQ listing (VSRC). He attempted retirement again, but when opportunity knocked, he answered by purchasing the assets of Caradata.com in bankruptcy court in 2000. This formed PracticeMatch Services, LLC, which he eventually sold to M3, a closely-held affiliate of Sony.

He credits much of his professional resiliency from values passed down from a heritage of sharecroppers and coal miners. These modest beginnings threaded through his leadership qualities, such as his innovative, solution-focused problem solving and sincere, mentor-like development of human professional potential. He believes there is little a company can’t do with a dedicated team, a spirited leader, and a groundbreaking product.

Julie Morris, Vice President of Clinical Research and Product Development

Julie Morris is the Vice President of Clinical Research and Product Development. She currently manages all aspects of research for Prevent-Plus. Her responsibilities include: KOL Development and Technology Adoption, Management of Clinical Studies and IRB Submissions, Identification and Implementation of Technology Needs and Innovation. Julie has over 19 years of medical device experience; including escalating positions with Covidien (a/k/a Medtronic) & Smith & Nephew, as well as with various early stage start-up enterprises. Julie has demonstrated success in sales, marketing, operations, compliance, sourcing and strategic planning. She has a proven track record in new product launch, marketing and sales with innovative new products to a variety of medical device specialties including; Vascular Surgery, General Surgery, Plastic Surgery, Podiatry, ER Medicine, Hospital Outpatient Surgery Clinics, Wound Centers and Outpatient Cath Labs. In addition to her experience in Sales and Marketing, Julie has handled a wide range of other responsibilities including; Vendor Sourcing and Management, New Product Development, Commercial Product Launch,Product Branding and Positioning, Operations and Infrastructure, Regulatory, Quality and Compliance, and Clinical Training.

Perry Robins, MD, Consultant

Dr. Robins is professor emeritus of dermatology at New York University Medical Center, where he served more than 40 years. A pioneer in Mohs Micrographic surgery, he was chief of the Mohs Micrographic Surgery Unit at NYU and performed about 47,000 skin cancer surgeries in his career.

He has lectured in nearly 50 countries and in four languages. In addition, Dr. Robins is the founder-president of the International Society for Dermatologic Surgery, a founder and former president of the American College of Mohs Surgery and former president of the American Society of Dermatologic Surgery. In 1979, Dr. Robins formed The Skin Cancer Foundation as the first charitable organization to focus exclusively on skin cancer, and he served as its president until 2016.

The American Academy of Dermatology made Dr. Robins an honorary fellow for outstanding contributions in dermatology, and, on behalf of The Skin Cancer Foundation, he received its Award for Excellence in Education, 14 Gold Triangle Awards for Excellence in Community Education and a Presidential Citation. He has been honored as a distinguished member of both the American College of Mohs Surgery and the American Society of Dermatologic Surgery, and was awarded a Presidential Citation by the International Society of Dermatologic Surgery. The impact of Dr. Robins’ work is far-reaching, and more than a dozen international dermatologic societies have presented him with honorary memberships.

Dr. Robins published more than 60 articles in leading medical journals and is the founder of The Journal of Dermatologic Surgery and the Journal of Drugs in Dermatology. He has written five books for the general public: Sun Sense: a Guide to the Prevention and Early Detection of Skin CancerUnderstanding Melanoma: What You Need To Know with Maritza Perez, MD, Understanding Basal Cell Carcinoma: What You Need to KnowUnderstanding Squamous Cell Carcinoma: What You Need to Know, and Play it Safe in the Sun, an illustrated book for children.

Joseph Sant’Angelo, Consultant

With 29 plus patents to his name, Mr. Sant’Angelo has found great success in research and product development. As a student at the University of Illinois, Mr. Sant’Angelo earned an award from the American Institute of Chemical Engineering that launched his career in fields from nuclear-powered aircraft to developing polymers for flame resistant astronaut suits.

With Dr. Perry Robins, an emeritus dermatology professor from New York University Medical Center, he developed a carbon dioxide containing liquid polymer for medical applications that received FDA approval, that is now known as DuraDerm®.

Executive Bios

Brad Chartrand, Chief Executive Officer

Jeffrey S. Elbl, Pharm.D., Chief Technology Officer

Joseph E. Thomure, Chairman/Managing Member

Julie Morris, Vice President of Clinical Research and Product Development

Perry Robins, MD, Consultant

Joseph Sant’Angelo, Consultant